RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors

Ataxia telangiectasia and Rad3-related (ATR) kinase protects genome integrity during DNA replication. RP-3500 is a novel, orally bioavailable clinical-stage ATR kinase inhibitor (NCT04497116). RP-3500 is highly potent with IC(50) values of 1.0 and 0.33 nmol/L in biochemical and cell-based assays, re...

Descripción completa

Detalles Bibliográficos
Autores principales: Roulston, Anne, Zimmermann, Michal, Papp, Robert, Skeldon, Alexander, Pellerin, Charles, Dumas-Bérube, Émilie, Dumais, Valerie, Dorich, Stéphane, Fader, Lee D., Fournier, Sara, Li, Li, Leclaire, Marie-Eve, Yin, Shou Yun, Chefson, Amandine, Alam, Hunain, Yang, William, Fugère-Desjardins, Chloe, Vignini-Hammond, Sabrina, Skorey, Kathryn, Mulani, Amina, Rimkunas, Victoria, Veloso, Artur, Hamel, Martine, Stocco, Rino, Mamane, Yael, Li, Zuomei, Young, Jordan T.F., Zinda, Michael, Black, W. Cameron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
MCT First Disclosures
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398170/
https://www.ncbi.nlm.nih.gov/pubmed/34911817
http://dx.doi.org/10.1158/1535-7163.MCT-21-0615

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398170/
https://www.ncbi.nlm.nih.gov/pubmed/34911817
http://dx.doi.org/10.1158/1535-7163.MCT-21-0615

Ejemplares similares